Chromium deficiency and cardiovascular risk.
Recent measurements have demonstrated that plasma chromium levels in patients with coronary artery disease are very much lower than in normal subjects. A review of the literature concerning the physiological functions of chromium (or GTF) shows it to be implicated in most of the known factors of cardiovascular risk, via its effect on insulin levels and activities. Chromium deficiency leads to impaired lipid and glucide metabolism and results in high circulating insulin levels, the probable consequences of which suggest that chromium deficiency may be a primary risk factor in cardiovascular disease.
D000596:Amino Acids / Q000502:physiology; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology; D009202:Cardiomyopathies / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000378:metabolism; D002857:Chromium / Q000097:blood / Q000378:metabolism* / Q000502:physiology / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000209:etiology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D007328:Insulin / Q000097:blood / Q000378:metabolism; D050356:Lipid Metabolism; D009539:Nicotinic Acids / Q000502:physiology; D051381:Rats; D012306:Risk
D000596:Amino Acids; D007328:Insulin; D009539:Nicotinic Acids; C015240:glucose tolerance factor; D002857:Chromium; D005947:Glucose